Immunoassay for detection of SCID (severe combined immunodeficiency) in newborns
- Technology Benefits
- Immunoassays are used routinely in NBS as a first-tier screening protocol, therefore the multiplex immunoassay presents as a viable alternative or complement to the TREC assay in detecting SCID.Low cost rapid test (Immunoassay vs. DNA testing)For markets where DNA/TREC Assay testing equipment is not widely available i.e. Brazil, Asia.Additiional markets exist in populations where SCID is prevalent but DNA testing is culturally unacceptable i.e Native Americans
- Technology Application
- Immunoassay for Newborn screening panel Severe Combined Immunodeficiency (SCID).Alternative test for identifying other T-cell immunodeficiencies
- Detailed Technology Description
- Using the Guthrie specimen, our immunoassay utilizes novel antibodies against CD3 epsilon peptides as a marker for T-cell deficiency. This assay is very promising as a viable alternative or complement to the TREC assay for detecting SCID in a Guthrie specimen.
- Countries
- United States
- Supplementary Information
- Inventor: PASS, Kenneth, A. | LINDAU-SHEPARD, Barbara | JANIK, David, K.
Priority Number: WO2011109588A1
IPC Current: A61K003804
Assignee Applicant: Health Research Inc.
Title: NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES | NOUVEAUX IMMUNOGÈNES ET ANTICORPS CD3 EPSILON
Usefulness: NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES | NOUVEAUX IMMUNOGÈNES ET ANTICORPS CD3 EPSILON
Summary: The isolated CD3 ε peptide is useful for diagnosing immunodeficiency, preferably severe combined immunodeficiency and T cell immunodeficiency in patient (all claimed).
Novelty: New isolated cluster of differentiation 3 epsilon peptide, useful for diagnosing immunodeficiency e.g. severe combined immunodeficiency in patient, comprises amino acid sequence
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- 8,569,450
- *Abstract
-
Severe Combined Immunodeficiency (SCID) presents as one of the greatest opportunities for newborn screening (NBS), and also one of its most difficult challenges. The defining characteristic is always a severe defect in T-cell production and function, with defects in B-lymphocytes as a primary or secondary problem. This is the first and only condition on the newborn screening panel of 30 genetic diseases that is curable if identified and treated in early infancy.
- *IP Issue Date
- Oct 29, 2013
- *IP Type
- Utility
- Country/Region
- USA
For more information, please click Here
